drug · small molecule
ELTROMBOPAG OLAMINE
Marketedupdated 5mo agoby $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 2 investigational indications.
targets
Thrombopoietin receptor
all catalysts(3)
Trials studying ELTROMBOPAG OLAMINE
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 1, 2027
302 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (54)
- Feb 1, 2028patentUS 8052993*PED1.3y
- Feb 1, 2028patentUS 8052993*PED1.3y
- Feb 1, 2028patentUS 8052993*PED1.3y
- Feb 1, 2028patentUS 8052993*PED1.3y
- Feb 1, 2028patentUS 8052994*PED1.3y
- Feb 1, 2028patentUS 8052994*PED1.3y
- Feb 1, 2028patentUS 8052994*PED1.3y
- Feb 1, 2028patentUS 8052994*PED1.3y
- Feb 1, 2028patentUS 8062665*PED1.3y
- Feb 1, 2028patentUS 8062665*PED1.3y
- Feb 1, 2028patentUS 8062665*PED1.3y
- Feb 1, 2028patentUS 8062665*PED1.3y
- Feb 1, 2028patentUS 8071129*PED1.3y
- Feb 1, 2028patentUS 8071129*PED1.3y
- Feb 1, 2028patentUS 8071129*PED1.3y
- Feb 1, 2028patentUS 8071129*PED1.3y
- Feb 1, 2028patentUS 8828430*PED1.3y
- Feb 1, 2028patentUS 8828430*PED1.3y
- Feb 1, 2028patentUS 8828430*PED1.3y
- Feb 1, 2028patentUS 8828430*PED1.3y
- Aug 1, 2027formulationUS 8052993302d
- Aug 1, 2027formulationUS 8052993302d
- Aug 1, 2027formulationUS 8052993302d
- Aug 1, 2027formulationUS 8052993302d
- Aug 1, 2027formulationUS 8052994302d
- Aug 1, 2027formulationUS 8052994302d
- Aug 1, 2027formulationUS 8052994302d
- Aug 1, 2027formulationUS 8052994302d
- Aug 1, 2027formulationUS 8062665302d
- Aug 1, 2027formulationUS 8062665302d
- Aug 1, 2027formulationUS 8062665302d
- Aug 1, 2027formulationUS 8062665302d
- Aug 1, 2027formulationUS 8071129302d
- Aug 1, 2027formulationUS 8071129302d
- Aug 1, 2027formulationUS 8071129302d
- Aug 1, 2027formulationUS 8071129302d
- Aug 1, 2027formulationUS 8828430302d
- Aug 1, 2027formulationUS 8828430302d
- Aug 1, 2027formulationUS 8828430302d
- Aug 1, 2027formulationUS 8828430302d
- Jan 13, 2026patentUS 7547719*PED
- Jan 13, 2026patentUS 7547719*PED
- Jan 13, 2026patentUS 7547719*PED
- Jan 13, 2026patentUS 7547719*PED
- Jan 13, 2026patentUS 7547719*PED
- Jan 13, 2026patentUS 7547719*PED
- Jan 13, 2026patentUS 7547719*PED
- Jul 13, 2025compositionUS 7547719
- Jul 13, 2025compositionUS 7547719
- Jul 13, 2025compositionUS 7547719
- Jul 13, 2025compositionUS 7547719
- Jul 13, 2025compositionUS 7547719
- Jul 13, 2025compositionUS 7547719
- Jul 13, 2025compositionUS 7547719
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that